MicroRNA 218 (miR-218)

MicroRNA 218 (miR-218) is a short, non-coding RNA of approximately 20–24 nucleotides that regulates gene expression post-transcriptionally by binding to complementary sequences in the 3′-untranslated regions (UTRs) of target mRNAs, leading to translational inhibition or destabilization of the target transcripts[3][5]. miR-218 is processed from two primary transcripts (MIR218-1 and MIR218-2) in the human genome[3][5]. It is involved in numerous cellular processes, including tumor suppression across multiple cancer types through the downregulation of oncogenes and modulation of signaling pathways such as PI3K/AKT, NF-κB, and Wnt/β-catenin[2][7][9]. In the central nervous system, miR-218 regulates the assembly and function of neural networks, presynaptic neurotransmitter release, and cognitive function by targeting various neuronal mRNAs[1][4]. Aberrant expression of miR-218 is implicated in cancer progression, neurodegenerative and neuropsychiatric disorders, and cardiovascular patterning defects[2][4][8]. Due to its roles as a tumor suppressor and a neural modulator, miR-218 is considered a promising but complex therapeutic target and a potential biomarker for disease progression and prognosis[2][9].

Other names

miR-218MIR218MicroRNA 218-1MicroRNA 218-2MIR218-1MIR218-2hsa-mir-218-1hsa-mir-218-2

Antisense oligonucleotides blocking miR-218 binding (target site blockers)[1] miR-218 mimics or overexpression act as tumor suppressors by downregulating oncogenes, including BCL-2, BMI-1, survivin (BIRC5), and others[2][7][9] Alters translation or stability of mRNA targets such as PTEN, YY1, Syt13, Kif21b, C3, SLUG, ZEB2, EGFR, CDK6, ROBO1, etc.[1][2][4][7]